StockMirror — Stock Screener

DCAL Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Dishman Carbogen Amcis reported a strong Q4 FY26 with 19% YoY revenue growth (INR 851 crores) and full-year EBITDA margin expansion of 200 bps to 19.3%. Growth was driven by CDMO (+21%) and high-margin Vitamin D analogs. Key catalysts include ADC molecule supply (CHF 30-40M expected), tech transfer of a CHF 20-25M product to India (improving margins), and a new ECB loan to reduce high-cost debt. However, near-term caution is warranted due to geopolitical uncertainties, time-to-conversion of projects, and the French subsidiary's losses (targeting profitability by FY28). The company targets a 15% revenue CAGR and 25% EBITDA margin by FY28.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management targets a 25% EBITDA margin by FY28 while aiming for a 15% revenue CAGR, indicating a balanced focus on growth and profitability.

About Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited (DCAL) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More